Annual Scientific Meeting
Message from #ANZUP23 Co-Convenors
On behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group convening committee, we were honoured to convene the 12th Annual Scientific Meeting (ASM) from 9 – 11 July 2023 at the Melbourne Convention Centre. The ASM provided a platform to discuss and present the latest updates in GU cancer treatment, research and supportive care and to learn more about existing and planned ANZUP trials. Under the theme of ‘Bouncing Back’, we discussed how people and systems have adjusted and changed in response to the pressures of the pandemic, and also in relation to the impacts of these cancers.
Over the course of three days, delegates had the opportunity to engage with and learn from eight international experts and numerous national leaders in the research, diagnosis, treatment, and management of genitourinary (GU) cancers. The collegial spirit that defines ANZUP was evident throughout the program, which catered to professionals working in various aspects of GU cancers.
The diverse sessions included the highly successful new addition, The Perfect Pitch, the popular MDT Masterclass, the Translational and Supportive Care breakfast sessions, the always well-attended Nurses Symposium, the thought-provoking plenary sessions, the important ANZUP Trials in Action session, and the anticipated debates and poster presentations, among many other informative sessions.
We are fortunate to have had the participation of over 80 speakers, panellists, session chairs, and poster presenters who contributed to more than 20 different sessions throughout the three days. This remarkable turnout reflects the diversity and breadth of ANZUP’s membership, which has grown to exceed 2,200 members.
Our international faculty played a vital role in providing a global perspective on the significant challenges faced by GU cancer experts. Their expertise and contributions were invaluable, and we extend our gratitude to Andrea Apolo, Laurien Buffart, Ananya Choudhury, Darren Feldman, Rebecca Martin, Sima Porten, Bertrand Tombal, and Alex Wyatt for their involvement in all aspects of the meeting.
In addition, the annual free Community Engagement Forum provided an opportunity for the public to interact with a team of experienced healthcare professionals and patient advocates. The presentations and panel discussions covered important topics such as quality of life, treatment choices, survivorship, impacts on intimacy, and the cost of cancer care. This forum allowed the community to learn about ANZUP and our clinical trials research program while engaging with experts in the field.
We are proud to report that this year’s ASM generated significant interest and participation on social media. With close to 1.7 million #ANZUP23 impressions and over 500 tweets, the engagement on Twitter was remarkable. The remarkable attendance of 446 delegates not only demonstrates the reputation ANZUP has earned for delivering high-quality, academically rigorous, educational, and entertaining ASMs, but also represents the highest number of delegates to date.
Thank you to every speaker, sponsor, chair, delegate, participant, committee member and organiser for your valuable contributions to the success of #ANZUP23. We look forward to seeing you in Gold Coast for #ANZUP24.
Ben Tran & Renu Eapen
The #ANZUP23 ASM Wiley Program book can be viewed here.
It contains the program, abstracts, photos and biographies of the presenters as well as sponsor details.
Message from Andrew Weickhardt #ANZUP22 Convenor
On behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group convening committee, I was honoured to convene the 11th Annual Scientific Meeting (ASM) from 10 – 12 July 2022 at the Adelaide Convention Centre. This year’s ASM theme ‘No Longer on Mute: Patients, Carers and Our Research Community’ provided a platform to discuss the need for a voice for many groups – the patient, carers, vulnerable communities, other disciplines, and the research community – about clinical trials. It was thrilling to be able to finally come together face-to-face and network, re-ignite old friendships, debate, discuss and appreciate the multidisciplinary group of healthcare professionals in attendance.
Throughout the 3-day meeting, delegates had the opportunity to interact with and learn from four international experts and numerous national leaders in the research, diagnosis, treatment and management of GU cancers, always with the collegial spirit that defines ANZUP.
The ASM was truly multidisciplinary – there were sessions to suit everyone working in GU cancers. The program included a highly successful new Clinical Trials Research Symposium, the popular MDT Masterclass, the Translational and Supportive Care breakfast sessions, the always well-attended Nurses Symposium, the extremely topical and important plenary session, ‘Raising your voice for equity in cancer care’, ANZUP trial updates, and of course the much-anticipated Crossfire Debates and poster presentations, as well as many more very informative sessions.
We were fortunate to have more than 80 speakers, panelists, session chairs and poster presenters take part in more than 20 different sessions throughout the three days. This is a great reflection on the diversity and breadth of ANZUP’s now 2,050-strong membership.
In addition, our international faculty were a highly engaged group, providing a global perspective on many of the significant issues facing GU cancer experts. Over the three days, the quality and impact of our international faculty cannot be overstated, with Himisha Beltran, Noel Clarke, Christopher Sweeney, Andrew Loblaw, Bertrand Tombal, Samra Turajlic, and Susanne Vahr Lauridsen playing a significant part in all facets of the meeting both in person and virtually.
Other highlights included a Q&A evening symposium hosted by Ben Tran who tackled the topic of “Survivorship Unmuted.” With the panel of GU cancer survivors, they addressed what survivorship means and what life after treatment looks like.
The annual free Community Engagement Forum featured presentations and panel discussions covering quality of life, treatment choices, survivorship, impacts on intimacy and the cost of cancer care. This session gave the public the opportunity to engage with an experienced team of healthcare professionals and patient advocates while learning about ANZUP and our clinical trials research program.
Also new to this year’s ASM was the inaugural ANZUP Outstanding Leadership Award. This award, and standing ovation, was truly deserved by Guy Toner. This award recognised his immense contribution to both ANZUP and GU cancer research. Guy was part of ANZUP’s inception and provided unwavering guidance, advice, and knowledge throughout his years as the Deputy Chair of ANZUP and trial investigator of various studies.
This year we again had fabulous Twitter engagement of close to 1.8 million #ANZUP22 impressions and over 800 tweets. Attendance was impressive with close to 400 delegates – all testament to the high quality, academic, educational, entertaining ASM for which ANZUP has become renowned.
Thank you to every speaker, sponsor, chair, delegate, participant, committee member and organiser for your contribution. We look forward to seeing you in Melbourne for #ANZUP23.
If you registered for #ANZUP22 ASM you can log on to Zoom Events and re-watch any session released by the ASM speakers, or view a presentation you may have missed.
A password was sent to all ASM delegates providing access to the presentations.
All on-demand video sessions are available to watch here.
The #ANZUP22 ASM Wiley Program book can be viewed here.
It contains the program, abstracts, photos and biographies of the presenters as well as sponsor details.
Photos highlighting the fabulous 3 days of #ANZUP22 ASM can be viewed here.
You can view additional #ANZUP22 videos including all the ANZUP in Conversations, the Evening Symposium, and the Community Engagement Forum via the ANZUP YouTube Channel here.
Research Review, with Associate Professor Ben Tran, have selected 10 presentations from the Annual Scientific Meeting of the Australia and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group that were particularly interesting.
If you registered for #ANZUP21 ASM you can log on to the ASM meeting platform and re-watch any session or view a presentation you may have missed.
All on-demand video sessions are available to watch on the ASM platform.
ANZUP Annual Scientific Meeting (ASM) 17-18 October 2021
So once again, in view of COVID-19, our #ANZUP21 Annual Scientific Meeting (ASM) took the format of a two-day hybrid event working with local hubs and an interactive virtual meeting platform. With a superb line up international and national faculty, over 400 delegates heard the latest in GU cancer treatment and research, as well as existing and planned ANZUP trials.
The program kicked off with our Nurses and Allied Health session chaired by Kath Schubach and Natasha Roberts. The virtual workshop was attended by ~140 participants and featured updates on nurse-led research. It was followed by a panel exploring the challenges faced when undertaking nursing research, and potential pathways to engage with research, either as contributors or leaders. A fireside chat between Haryana Dhillon and CAP member Colin O’Brien provided us with insights into his experience working with ANZUP members to take a new idea to the prostate cancer concept development workshop and the process of bringing a consumer-led question to fruition as a research study.
We saw the return of the ever-popular Multidisciplinary (MDT) Masterclass skillfully convened by Carole Harris. The short, sharp cases across prostate, renal cell carcinoma, penile and testicular cancer stimulated excellent discussion and “chat” between the expert panelists and attendees. Each session endeavoured to educate the audience with real-life clinical challenges and interactive polling.
On the Sunday afternoon ANZUP hosted a ‘virtual’ welcome drink which entrée the first of our fabulous international symposia. The theme ‘Clearer Vision’ chaired by Bertrand Tombal saw excellent presentations from Chris Parker, Heather Payne and Alison Birtle.
Chris spoke about ‘How MRI became the mainstay of active surveillance’ and discussed watchful waiting based on data “from the last century”.
Heather Payne followed with her insights into ‘The trials and tribulations of managing men with metastatic hormone sensitive prostate cancer.’
The final presentation of the day came from our very own Alison Birtle, ‘Wishful thinking’ in genitourinary oncology. She provided us with her expert insight on optimal therapy for systemic therapy in upper tract urothelial carcinoma (UTUC).
Day two of the ASM began with another stellar line up of international guests. Led by Professor Chris Sweeney, medical oncologist from Dana-Farber Cancer Centre, we heard from Dr Eli Van Allen, Professor Matt Galsky and Associate Professor Sima Porten to discuss personalised medicine and their vision for the future of genitourinary oncology.
Dr Allen, a medical oncologist and computational biologist also from Dana-Farber, gave a stunning talk regarding the convergence of machine learning and genomics. He began by discussing the rapid evolution of the technology and the challenges in clinical interpretation. Using algorithms developed by his team, Dr Allen showed a path forward to streamline the implementation of genomics into routine care of patients with GU cancers in the future.
To follow, Professor Galsky a medical oncologist at Mount Sinai, described the evolving treatment landscape for metastatic urothelial cancer. He highlighted the significant advances in the last few years with the introduction of immune checkpoint inhibitors and targeted therapies for patients with urothelial cancer. Running through some of the seminal trials, he demonstrates the importance of personalising treatment recommendations upon both patient and tumoural factors and provides optimism for the future.
Finally, Associate Professor Porten, a urologist at UCSF, discussed advances in molecular classification of muscle-invasive urothelial cancer to explain the biologic and clinical heterogeneity that we see in the clinics. Utilising contemporary sequencing to define gene expression profiles, she explained differences in basal and luminal subtypes and how this is important in recommending treatment and defining prognosis. She impressed upon the delegates the importance of embedding biomarkers into future prospective trials in urothelial cancer to further develop this space.
The ANZUP Symposium, chaired by Haryana Dhillon, brought together a panel who shared work they are doing to address ‘Disparities in Cancer Care’ with a focus on Aboriginal and Torres Strait Islander people. Gail Garvey, presented on “What do we know about survivorship needs of Indigenous people in Australia?” This gave a marvellous insight into how Indigenous people in Australia experience cancer care. Daniel Lindsay followed with an update on his research, “Out of pocket costs of Aboriginal & Torres Strait Islander people with prostate cancer,” generating much discussion about potential causes of these differences. Finally, Dorothy Keefe shared with us “What Cancer Australia is doing to improve cancer outcomes in Aboriginal & Torres Strait Islander people” showcasing a range of resources now available to support cancer care health professionals working with Indigenous people. Dorothy encouraged the audience to consider what they could do to help address these disparities, suggesting starting by asking people if they are Indigenous in our daily practice. Only then can we link people to Indigenous health supports better able to meet their needs.
The Subcommittee Chairs/ Deputy Chairs provided delegates with an entertaining and comprehensive summary of our current ANZUP Trial, as well as “what’s happening” in terms of our pipeline of studies. Ray Allen, CAP deputy chair, also highlighted the work of our ever enthusiastic and hardworking CAP.
The second half of the day included a virtual poster discussant room expertly chaired by Declan Murphy and Lucinda Morris, the Below the Belt Research Fund Awards and finally the Best of the Best awards. Congratulations to all our winners!
The final session of the ASM was an entertaining crossfire debate, ‘No time to lose: to improve survival we can’t wait for data on overall survival’, given by Associate Professor David Pryor and Associate Professor Dave Pook. Dr. Pook argued the affirmative, that waiting for overall survival data is unnecessary, potentially harmful and there are other surrogate endpoints that are important for patients. Dr. Pryor countered that we must wait for overall survival as there is not always a clear line of site [from surrogates] to a worthwhile OS benefit. He also argued that in addition, there needs to be improved quality of life and the treatment needs to be cost-effective.
Once again, this year’s convening committee did an amazing job to bring another high quality, world-class, educational, inspirational, and captivating “virtual” program to our members and key stakeholders. We particularly thank Nick Brook, Lisa Butler, Ian Davis, Haryana Dhillon, Amanda Hutchinson, Dickon Hayne, David Pryor, Natasha Roberts, Kath Schubach, Henry Woo, Leonie Young, Sally Sara, Shomik Sengupta and Andrew Weickhardt as well as our MDT Masterclass conveners Carole Harris and Nicky Lawrence. A big thank you also to the ANZUP team, and our conference organiser Sarah Dixon, who worked tirelessly behind the scenes to ensure the virtual meeting flowed seamlessly.
We are also extremely grateful to our Sponsors for their ongoing support of ANZUP and our ASM. We also acknowledge Cancer Australia who provide infrastructure funding to support ANZUP and our ASM.
Andrew Weickhardt, our 2022 Convener, closed the 2021 ASM encouraging everyone to “Save the Date” for next year’s meeting, 10 – 12 July 2022. He extended an invitation to those members interested to join the convening committee to help plan what we anticipate will be the “Best Ever” face to face get together in Adelaide!